249 related articles for article (PubMed ID: 18360826)
1. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
Hopkins-Donaldson S; Cathomas R; Simões-Wüst AP; Kurtz S; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Int J Cancer; 2003 Aug; 106(2):160-6. PubMed ID: 12800189
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
[TBL] [Abstract][Full Text] [Related]
7. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
[TBL] [Abstract][Full Text] [Related]
8. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
10. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
[TBL] [Abstract][Full Text] [Related]
11. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
13. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
[TBL] [Abstract][Full Text] [Related]
14. Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma.
Cao X; Rodarte C; Zhang L; Morgan CD; Littlejohn J; Smythe WR
Cancer Biol Ther; 2007 Feb; 6(2):246-52. PubMed ID: 17224645
[TBL] [Abstract][Full Text] [Related]
15. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
[TBL] [Abstract][Full Text] [Related]
16. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
18. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
19. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
20. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
Smythe WR; Mohuiddin I; Ozveran M; Cao XX
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
